Ash 2022 preview – Affimed and Aptose score

After leaving investors waiting at Asco Adicet will come into December’s Ash meeting with much to prove. However, the markets will have to wait a bit longer, until Ash itself, because the abstract unveiled yesterday on ADI-001 reveals little about this gamma-delta Car-T therapy’s durability.

Instead, biotech investors picked out Aptose as the early winner of yesterday’s Ash abstract drop: the micro-cap ended the day up 27% on hopes for its Hanmi-derived kinase inhibitor tuspetinib. However, it was Affimed that made a claim to having one of the meeting’s most convincing efficacy datasets, with its NK-cell engager AFM13.